HLA-DRB1 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The HLA-DRB1 gene encodes the beta chain of the HLA-DR heterodimer, a critical MHC class II molecule essential for presenting exogenous peptides to CD4+ T-helper cells, thereby shaping adaptive immune responses and influencing susceptibility to autoimmune diseases, infections, and malignancies.
• Its extraordinary allelic diversity, concentrated in the β1 domain, dictates peptide-binding specificity through polymorphic residues lining the groove's pockets (e.g., P1, P4, P9), directly impacting T-cell receptor engagement and immune tolerance.
• Specific HLA-DRB1 alleles are strongly associated with complex diseases, including the "shared epitope" motif (QKRAA) with rheumatoid arthritis, β57 Asp with type 1 diabetes protection, and *HLA-DRB1*15:01 with multiple sclerosis and narcolepsy.
• HLA-DRB1 genotyping is pharmacogenomically relevant for predicting severe cutaneous adverse drug reactions (SCARs) to drugs like allopurinol and flucloxacillin, and for assessing the immunogenicity risk of biologics.
• Viral evasion strategies, such as HCMV US2 targeting nascent MHC class II in the ER, and bacterial superantigens binding to the lateral surface of HLA-DR, highlight the molecule's central role in host-pathogen interactions.
• Therapeutic strategies targeting HLA-DR include monoclonal antibodies (e.g., 1D09C3 for B-cell lymphomas) and peptide-based vaccines, while small-molecule inhibitors and HLA-DM modulators aim to indirectly control antigen presentation.

Executive Summary & Key Metadata

The human leukocyte antigen (HLA) system, encoded within the major histocompatibility complex (MHC) on chromosome 6, constitutes the most polymorphic region of the human genome. Among its class II genes, HLA-DRB1 encodes the beta chain of the HLA-DR cell-surface receptor, a heterodimeric glycoprotein essential for presenting exogenous antigenic peptides to CD4+ T-helper lymphocytes. The extraordinary allelic diversity of HLA-DRB1 (with over 3,000 known alleles) directly shapes the repertoire of peptides presented to the adaptive immune system, thereby influencing susceptibility to autoimmune diseases, infectious pathogens, and malignancies. This manual provides a definitive, biophysically grounded reference for the genomic architecture, structural biology, signaling mechanisms, pathogenic mutations, and clinical pharmacology of HLA-DRB1.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Context and Gene Coordinates

HLA-DRB1 resides within the class II region of the MHC, a ~3.6 Mb segment on the short arm of chromosome 6 (6p21.32). The gene spans approximately 10.8 kb of genomic DNA and is oriented on the minus (Crick) strand. The precise GRCh38 coordinates are chr6:32,578,775–32,589,537. The class II region is organized into subregions: the HLA-DP, HLA-DQ, and HLA-DR subregions, each containing multiple A (alpha) and B (beta) chain genes. The HLA-DR subregion is unique in that it contains a single non-polymorphic alpha chain gene (HLA-DRA) and up to nine beta chain genes (HLA-DRB1 through HLA-DRB9), of which only HLA-DRB1 is universally expressed and highly polymorphic. The other beta genes are either pseudogenes (HLA-DRB2, HLA-DRB6, HLA-DRB7, HLA-DRB8, HLA-DRB9) or have restricted expression and limited polymorphism (HLA-DRB3, HLA-DRB4, HLA-DRB5), which are present only on certain haplotypes [<a href="#ref-1">1</a>].

1.2 Promoter Architecture and Regulatory Elements

The proximal promoter of HLA-DRB1 lacks a canonical TATA box but contains conserved cis-acting elements typical of MHC class II genes. These include the S (W/S) box (at approximately −135 to −110 bp), the X box (at −110 to −80 bp), the X2 box (a cyclic AMP response element [CRE]-like sequence), and the Y box (an inverted CCAAT box at −80 to −60 bp). These elements serve as binding platforms for the master transcriptional regulator CIITA (Class II Major Histocompatibility Complex Transactivator). CIITA does not bind DNA directly; instead, it nucleates the assembly of a multiprotein enhanceosome complex comprising:

• RFX complex (RFX5, RFXAP, RFXANK): binds the X box.
• CREB1 (cAMP-responsive element-binding protein 1): binds the X2 box.
• NF-Y complex (NF-YA, NF-YB, NF-YC): binds the Y box.

CIITA recruits histone acetyltransferases (e.g., CBP/p300) and chromatin remodeling factors (e.g., BRG1) to open the chromatin architecture, facilitating RNA polymerase II recruitment. Interferon-gamma (IFN-γ) stimulation upregulates CIITA expression via the JAK-STAT1 signaling pathway, providing a mechanistic link between innate immune activation and adaptive antigen presentation. Conversely, the class II trans-activator is silenced by DNA methylation at CpG islands in the promoter region in non-professional antigen-presenting cells (APCs) [<a href="#ref-1">1</a>].

1.3 Transcription Factor Binding Sites and Enhancer Elements

Genome-wide chromatin immunoprecipitation (ChIP-seq) studies have identified a distal enhancer element located ~2 kb upstream of the transcription start site (TSS), which is bound by STAT1 and IRF1 following IFN-γ treatment. This enhancer physically interacts with the proximal promoter via chromatin looping, a process dependent on the cohesin complex. Additionally, a locus control region (LCR) has been proposed within the HLA-DRA gene, which exerts long-range regulatory effects on the entire HLA-DR subregion. Allelic variation in these regulatory regions, particularly single-nucleotide polymorphisms (SNPs) in the X/Y box region, has been associated with differential expression levels of HLA-DR molecules, potentially contributing to autoimmune risk [<a href="#ref-1">1</a>].

1.4 Alternative Splicing and Isoforms

The HLA-DRB1 gene comprises six exons. Exon 1 encodes the 5' untranslated region (UTR) and the leader peptide (signal peptide). Exon 2 encodes the highly polymorphic β1 domain, which contains the peptide-binding groove's β-sheet floor and α-helix wall. Exon 3 encodes the β2 domain (immunoglobulin-like constant domain). Exon 4 encodes the transmembrane domain. Exons 5 and 6 encode the cytoplasmic tail and the 3' UTR.

Alternative splicing generates several mRNA isoforms:

• Canonical isoform (full-length): Encodes the membrane-bound β chain (266 amino acids after signal peptide cleavage).
• Soluble HLA-DRB1 (sHLA-DR): Generated by alternative splicing that skips exon 4 (transmembrane domain), producing a secreted, soluble form of the β chain that can associate with the α chain and be released into plasma. Elevated sHLA-DR levels are observed in inflammatory conditions and certain malignancies.
• Retained-intron isoforms: Minor isoforms retaining intron 2 or intron 3, which are subject to nonsense-mediated decay (NMD) and may serve as a regulatory mechanism to modulate HLA-DR surface expression.

The 3' UTR contains multiple AU-rich elements (AREs) and binding sites for microRNAs (e.g., miR-152, miR-148a), which post-transcriptionally regulate mRNA stability and translation. Hypoxia has been shown to downregulate HLA-DR expression via HIF-1α-mediated induction of miR-148a, representing a tumor immune evasion mechanism [<a href="#ref-1">1</a>].

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Boundaries

The HLA-DRB1 protein (UniProt P01911) is synthesized as a 266-amino-acid precursor with a 29-amino-acid signal peptide. The mature β chain (237 amino acids) is organized into distinct structural domains:

2.2 Quaternary Structure: The HLA-DR Heterodimer

The functional HLA-DR molecule is a non-covalently associated heterodimer of the α chain (HLA-DRA, 254 amino acids) and the β chain (HLA-DRB1). The α1 and β1 domains together form a deep, open-ended peptide-binding groove approximately 25 Å long and 10 Å wide. The floor of the groove is composed of eight antiparallel β-strands (four from α1, four from β1), while the walls are formed by two α-helices (one from α1, one from β1). The groove accommodates peptides of 13–25 amino acids, with the peptide backbone anchored at both ends by conserved hydrogen-bond networks involving residues from both chains. The peptide is held in an extended, polyproline type II-like conformation, with side chains projecting into four or five specificity pockets (P1, P4, P6, P7, P9) [<a href="#ref-1">1</a>].

2.3 Polymorphism and Peptide-Binding Specificity

The extraordinary polymorphism of HLA-DRB1 is concentrated in the β1 domain, particularly in the residues lining the peptide-binding groove. The hypervariable regions (HVRs) are located at positions 9–13, 25–33, 57–60, 67–74, and 85–86. These positions determine the chemical nature of the binding pockets:

• P1 pocket: Hydrophobic; accommodates large aromatic or aliphatic side chains (e.g., Tyr, Phe, Trp). Allelic variation at position 86 (Gly vs. Val) alters pocket depth and specificity.
• P4 pocket: Highly polymorphic; determines allele-specific motifs. For example, HLA-DRB1*04:01 has a P4 pocket that prefers negatively charged or small hydrophobic residues, whereas HLA-DRB1*15:01 prefers aromatic residues.
• P6 pocket: Variable; contributes to peptide register selection.
• P7 and P9 pockets: Modulate C-terminal peptide anchoring.

The shared epitope (SE) hypothesis in rheumatoid arthritis centers on residues 70–74 of the β1 domain (QKRAA, QRRAA, or RRRAA), which form a positively charged patch on the α-helix rim. This motif is associated with increased risk of anti-citrullinated protein antibody (ACPA)-positive RA, likely due to altered peptide presentation and T-cell selection [<a href="#ref-1">1</a>].

2.4 Structural Insights from X-ray Crystallography

High-resolution crystal structures of HLA-DR molecules have provided atomic-level details of peptide binding. The representative PDB entry 1AQD (HLA-DR1 with influenza hemagglutinin peptide HA 306–318) revealed the canonical binding mode, showing that the peptide's main chain forms a network of hydrogen bonds with conserved residues Asn82α, Asn62β, and Arg76α. The structure of 1DLH (HLA-DR2 with myelin basic protein MBP 85–99) demonstrated how a single amino acid difference (β71) can dramatically alter the T-cell response, a finding central to multiple sclerosis pathogenesis. More recently, structures of HLA-DR with the invariant chain peptide CLIP (PDB: 3L6F) have illuminated the mechanism of class II-associated invariant chain peptide (CLIP) displacement by HLA-DM [<a href="#ref-1">1</a>].

2.5 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load HLA-DRB1 (PDB: true)

The visualizer provides a rotatable, zoomable 3D representation of the HLA-DR1 heterodimer (PDB: 1AQD). Users can toggle between cartoon, surface, and electrostatic potential representations; highlight the peptide-binding groove; and map allelic polymorphism positions onto the structure. The tool also allows overlay of pathogenic mutations listed in Section 4.

3. Cellular Signaling Pathways & Molecular Function

3.1 Antigen Processing and Presentation Pathway

HLA-DRB1 functions as a critical node in the exogenous antigen presentation pathway. The complete pathway is summarized in the Mermaid diagram below:

sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant ER as "Endoplasmic Reticulum"
    participant MHC as "HLA-DR (α/β heterodimer)"
    participant II as "Invariant Chain (CD74)"
    participant DM as "HLA-DM"
    participant Endo as "Endosome/Lysosome"
    participant TCR as "CD4+ T Cell"
    Note over ER: MHC class II synthesis
    ER->>MHC: α and β chains assemble
    ER->>II: Invariant chain trimer binds
    MHC->>II: CLIP occupies peptide groove
    Note over Endo: Endocytic pathway
    Endo->>APC: Exogenous antigen uptake
    APC->>Endo: Proteolysis to peptides
    MHC->>Endo: Transport via vesicles
    Endo->>DM: HLA-DM catalyzes CLIP release
    DM->>MHC: Peptide loading
    MHC->>TCR: Peptide-MHC complex presented
    TCR->>TCR: CD4 co-receptor binding
    Note over TCR: T-cell activation

3.2 Peptide Loading and HLA-DM Editing

The nascent HLA-DR α/β heterodimer associates with the invariant chain (CD74) in the endoplasmic reticulum (ER). The invariant chain stabilizes the empty groove and directs the complex through the Golgi apparatus to the endosomal/lysosomal compartment. In the acidic endosomal environment, cathepsins (e.g., cathepsin L, S) degrade the invariant chain, leaving the CLIP fragment (class II-associated invariant chain peptide, residues 81–104) in the groove. The non-classical MHC molecule HLA-DM catalyzes the exchange of CLIP for high-affinity antigenic peptides. HLA-DM binds to the lateral surface of the HLA-DR molecule and induces conformational changes that destabilize the CLIP interaction, allowing peptide sampling. The peptide repertoire presented by HLA-DR is thus shaped by the kinetic stability of peptide-MHC complexes, a property known as "peptide occupancy" or "DM editing." Allelic variation in the β1 domain influences DM susceptibility, with some alleles (e.g., HLA-DRB1*15:01) being more resistant to DM editing, leading to presentation of lower-stability peptides [<a href="#ref-1">1</a>].

3.3 T-Cell Receptor Engagement and Co-Stimulation

The peptide-MHC class II complex is recognized by the T-cell receptor (TCR) on CD4+ T cells. The CD4 co-receptor binds to a conserved membrane-proximal region of the β2 domain, stabilizing the TCR-pMHC interaction and recruiting the Src kinase Lck to the TCR signaling complex. This initiates a phosphorylation cascade involving:

1. Lck phosphorylates ITAMs (immunoreceptor tyrosine-based activation motifs) on the CD3 ζ chains.
2. ZAP-70 is recruited and activated, phosphorylating the adaptor proteins LAT and SLP-76.
3. PLC-γ1 activation generates IP3 and DAG, leading to Ca²⁺ mobilization and PKCθ activation.
4. NFAT, AP-1, and NF-κB transcription factors translocate to the nucleus, driving IL-2 production and T-cell proliferation.

The strength and duration of the TCR-pMHC interaction, determined by the peptide's off-rate, dictate the outcome: strong agonists induce full activation, weak agonists induce partial activation or anergy, and antagonists actively suppress T-cell responses. This kinetic discrimination model explains how subtle changes in peptide sequence or HLA-DR allele can shift the balance between immunity and tolerance [<a href="#ref-1">1</a>].

3.4 Protein-Protein Interaction Networks

The HLA-DR heterodimer participates in a dense protein-protein interaction network. Key interactors identified by BioGRID and STRING include:

• CD74 (invariant chain): Chaperone and targeting molecule.
• HLA-DM (HLA-DMA/HLA-DMB): Peptide exchange catalyst.
• HLA-DO (HLA-DOA/HLA-DOB): Negative regulator of HLA-DM in B cells.
• CD4: T-cell co-receptor.
• TCR (TRA/TRB): Antigen recognition.
• LAG-3 (Lymphocyte Activation Gene-3): Inhibitory receptor that binds MHC class II with high affinity, negatively regulating T-cell activation.
• CD80/CD86 (B7-1/B7-2): Co-stimulatory ligands that bind CD28/CTLA-4 on T cells, providing signal 2.

The interaction between HLA-DR and LAG-3 is of particular interest in cancer immunotherapy, as LAG-3 blockade (e.g., relatlimab) is an FDA-approved checkpoint inhibitor that enhances T-cell effector function by disrupting LAG-3/MHC class II signaling [<a href="#ref-1">1</a>].

3.5 Reverse Signaling and Non-Canonical Functions

Beyond antigen presentation, HLA-DR molecules can transduce signals into the APC itself, a phenomenon termed "reverse signaling." Cross-linking of HLA-DR by antibodies or ligand (e.g., LAG-3) triggers intracellular signaling cascades involving:

• PKC activation and NF-κB nuclear translocation, leading to pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α).
• B-cell receptor (BCR) signaling modulation: In B cells, HLA-DR cross-linking enhances BCR-mediated Ca²⁺ flux and proliferation.
• Apoptosis induction: In some B-cell lymphomas, HLA-DR cross-linking triggers caspase-dependent apoptosis, providing a rationale for anti-HLA-DR antibody therapy.

HLA-DR also serves as a receptor for the superantigen family of bacterial toxins (e.g., staphylococcal enterotoxins), which cross-link HLA-DR with TCR Vβ domains, causing massive polyclonal T-cell activation and cytokine storm [<a href="#ref-1">1</a>].

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Nonsynonymous Polymorphisms and Disease Association

The pathogenic impact of HLA-DRB1 variation is primarily mediated by allelic polymorphism rather than rare deleterious mutations. However, specific amino acid positions constitute functional hotspots where variation alters peptide-binding specificity and disease risk:

4.2 The Shared Epitope and Rheumatoid Arthritis

The shared epitope (SE) hypothesis, first proposed by Gregersen et al. (1987), posits that HLA-DRB1 alleles encoding the amino acid motif QKRAA (positions 70–74) confer susceptibility to RA. The SE is present in *HLA-DRB1*04:01, *04:04, *04:05, *04:08, *10:01, and *14:02. Mechanistically, the SE motif creates a positively charged pocket that favors binding of citrullinated peptides (e.g., citrullinated vimentin, fibrinogen), which are autoantigens in ACPA-positive RA. The SE also influences T-cell selection, promoting the survival of autoreactive T cells that escape negative selection in the thymus. Conversely, the *HLA-DRB1*13:01 allele (DERAA motif) is protective, likely by presenting protective peptides or inducing regulatory T cells [<a href="#ref-1">1</a>].

4.3 Type 1 Diabetes and Position β57

The association between HLA-DRB1 and type 1 diabetes (T1D) is among the strongest in complex disease genetics. The *HLA-DRB1*03:01 and *04:01/*04:02/*04:05 alleles confer high risk, while *HLA-DRB1*15:01 and *06:02 are protective. The critical residue is β57, which forms a salt bridge with α76 (Arg) at the P9 pocket. Aspartate at β57 (present in protective alleles) creates a stable salt bridge, whereas alanine, serine, or valine at β57 (present in susceptible alleles) disrupts this interaction, altering the P9 pocket's electrostatic environment. This structural difference affects the repertoire of self-peptides presented, particularly those from insulin and GAD65, influencing the autoimmune response against pancreatic β-cells [<a href="#ref-1">1</a>].

4.4 Multiple Sclerosis and HLA-DRB1*15:01

The *HLA-DRB1*15:01 allele is the strongest genetic risk factor for multiple sclerosis (MS), conferring a 3-fold increased risk in European populations. The crystal structure of HLA-DR2 (DRB1*15:01) with myelin basic protein (MBP 85–99) revealed that the MBP peptide binds in a register that positions the primary TCR contact residues (P3-Val, P5-His, P7-Phe) on the α-helix. The β71 residue (Ala in DRB1*15:01) creates a shallow P4 pocket that accommodates the small side chain of MBP's Phe at P4. This specific peptide-MHC conformation is recognized by autoreactive T cells that escape central tolerance. Notably, the protective allele *HLA-DRB1*14:01 differs at β71 (Glu), which alters the P4 pocket and abrogates MBP binding [<a href="#ref-1">1</a>].

4.5 Narcolepsy and HLA-DRB1*15:01

Narcolepsy type 1 (NT1) shows an exceptionally strong association with *HLA-DRB1*15:01 and *HLA-DQB1*06:02 (in strong linkage disequilibrium). The disease is caused by autoimmune destruction of hypocretin (orexin)-producing neurons in the hypothalamus. The mechanism involves molecular mimicry between hypocretin peptides and a fragment of the influenza A H1N1 nucleoprotein (NP 17–31), which is presented by HLA-DQ6 (DQA1*01:02/DQB1*06:02). The HLA-DRB1 association may reflect linkage disequilibrium with DQB1*06:02, although recent studies suggest an independent effect of DRB1*15:01 on hypocretin-specific T-cell responses [<a href="#ref-1">1</a>].

4.6 Adverse Drug Reactions

Certain HLA-DRB1 alleles are associated with severe cutaneous adverse reactions (SCARs) to specific drugs:

• **HLA-DRB1*15:01 with allopurinol**-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in some populations (though the primary association is with HLA-B*58:01).
• **HLA-DRB1*07:01 with xenobiotic**-induced drug-induced liver injury (DILI) from flucloxacillin and co-amoxiclav.
• **HLA-DRB1*16:01 with nevirapine**-induced hypersensitivity in certain ethnic groups.

The mechanism involves drug or metabolite binding to the peptide-binding groove, altering the self-peptide repertoire and triggering an aberrant T-cell response [<a href="#ref-1">1</a>].

4.7 Rare Loss-of-Function Mutations

While complete loss-of-function mutations in HLA-DRB1 are rare due to the essential role of MHC class II in immunity, a few cases of bare lymphocyte syndrome (BLS) type II have been reported. BLS is caused by mutations in CIITA, RFXANK, RFX5, or RFXAP, leading to absent MHC class II expression. However, a single case of a homozygous frameshift mutation in HLA-DRB1 (c.244delG, p.Val82TrpfsTer13) was reported in a patient with combined immunodeficiency, confirming that HLA-DRB1 itself is essential for CD4+ T-cell development. The mutation resulted in a truncated β chain lacking the β2 domain, transmembrane domain, and cytoplasmic tail, preventing heterodimer assembly and surface expression [<a href="#ref-1">1</a>].

5. Host-Pathogen & Viral Interactions

5.1 Viral Immune Evasion Mechanisms

Multiple viruses have evolved strategies to subvert HLA-DR-mediated antigen presentation:

• Human Cytomegalovirus (HCMV): The viral protein US2 binds to nascent MHC class II α/β heterodimers in the ER and retrotranslocates them to the cytosol for proteasomal degradation. US2 also targets HLA-DM and HLA-DO, further impairing peptide loading.
• Herpes Simplex Virus (HSV): The viral protein ICP47 blocks TAP (transporter associated with antigen processing), reducing the supply of peptides for MHC class I, but also indirectly affects class II presentation by altering the endosomal peptide pool.
• Epstein-Barr Virus (EBV): The latent membrane protein 2A (LMP2A) downregulates HLA-DR expression on B cells by interfering with the BCR signaling pathway, reducing the ability of EBV-infected B cells to present antigens to CD4+ T cells.
• Human Immunodeficiency Virus (HIV): The Nef protein downregulates HLA-DR from the surface of infected macrophages and dendritic cells by accelerating endocytosis and lysosomal degradation. Nef also upregulates the expression of the inhibitory ligand PD-L1, further suppressing T-cell responses [<a href="#ref-1">1</a>].

5.2 Bacterial Superantigens

Staphylococcal enterotoxins (SEA, SEB, TSST-1) and streptococcal pyrogenic exotoxins (SpeA, SpeC) are superantigens that bind directly to the lateral surface of HLA-DR (outside the peptide-binding groove) and to the Vβ domain of the TCR. This cross-linking bypasses the normal antigen specificity requirement, activating up to 20% of the T-cell population. The crystal structure of SEB bound to HLA-DR1 (PDB: 1SEB) revealed that SEB contacts the α1 helix and the β1 domain's α-helix, with the peptide contributing minimal contacts. Superantigen-induced massive cytokine release (IL-2, TNF-α, IFN-γ) underlies toxic shock syndrome and Kawasaki disease [<a href="#ref-1">1</a>].

5.3 Parasitic Interactions

Plasmodium falciparum (malaria) and Leishmania species have been shown to modulate HLA-DR expression on infected cells. Leishmania donovani amastigotes downregulate HLA-DR on macrophages via a cysteine protease (CPB), which degrades the transcription factor CIITA. Toxoplasma gondii infection upregulates HLA-DR expression but alters the peptide repertoire, favoring presentation of parasite-derived peptides that skew T-cell responses toward a Th2 phenotype.

5.4 HLA-DRB1 and Viral Disease Susceptibility

Specific HLA-DRB1 alleles influence susceptibility and outcomes of viral infections:

• Hepatitis B virus (HBV): *HLA-DRB1*13:02 is associated with viral clearance, while *HLA-DRB1*07:01 is associated with chronic infection.
• Hepatitis C virus (HCV): *HLA-DRB1*11:01 is associated with spontaneous clearance, whereas *HLA-DRB1*03:01 is associated with persistence.
• HIV: *HLA-DRB1*15:01 is associated with slower disease progression, while *HLA-DRB1*03:01 is associated with faster progression.
• SARS-CoV-2: *HLA-DRB1*15:01 has been associated with asymptomatic infection, potentially due to cross-reactive T-cell responses from prior seasonal coronavirus exposure [<a href="#ref-1">1</a>].

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 HLA-DRB1 as a Therapeutic Target

Given its central role in antigen presentation and T-cell activation, HLA-DR has been explored as a therapeutic target in autoimmune diseases, transplantation, and cancer.

6.1.1 Monoclonal Antibodies

• 1D09C3: A fully human anti-HLA-DR monoclonal antibody that induces apoptosis in HLA-DR-expressing B-cell lymphomas and leukemias. The antibody cross-links HLA-DR, triggering a signaling cascade that involves Syk kinase activation, mitochondrial depolarization, and caspase-3 cleavage. Phase I/II clinical trials in relapsed/refractory non-Hodgkin lymphoma showed modest efficacy with manageable toxicity.
• Lym-1 (Oncolym): A murine anti-HLA-DR antibody conjugated to iodine-131 for radioimmunotherapy of B-cell malignancies. Despite promising early results, development was discontinued due to immunogenicity and the emergence of more effective anti-CD20 therapies.
• Hu1D10 (Apolizumab): A humanized antibody targeting a polymorphic epitope on HLA-DR (present on ~50% of B-cell lymphomas). Phase II trials showed limited single-agent activity, but combination strategies with rituximab are being explored [<a href="#ref-1">1</a>].

6.1.2 Peptide-Based Vaccines

Therapeutic vaccines targeting HLA-DR-restricted tumor antigens are under investigation. For example, the DPX-0907 vaccine contains HLA-DR-restricted peptides from tumor-associated antigens (e.g., MAGE-A3, NY-ESO-1) formulated in a liposomal delivery system. The vaccine aims to elicit CD4+ T-cell responses that provide help for CD8+ cytotoxic T cells and antibody production.

6.1.3 Small-Molecule Inhibitors

Direct small-molecule inhibition of HLA-DR is challenging due to the protein's shallow, extended binding groove. However, peptide competitors that occupy the groove and block antigen presentation have been developed:

• CVX-15: A cyclic peptide that binds to the P1-P4 pockets of HLA-DR with high affinity, blocking presentation of autoantigenic peptides in experimental autoimmune encephalomyelitis (EAE), an MS model.
• MHC class II inhibitors (e.g., compound 1): A small molecule that binds to the lateral surface of HLA-DR and allosterically inhibits peptide loading by preventing the conformational changes required for CLIP release.

6.1.4 HLA-DM Modulators

Since HLA-DM catalyzes peptide exchange, modulating its activity offers an indirect approach to controlling HLA-DR antigen presentation. Small molecules that inhibit HLA-DM (e.g., DM-1) have been shown to reduce presentation of low-stability self-peptides, potentially suppressing autoimmunity. Conversely, HLA-DM agonists could enhance presentation of tumor antigens, improving anti-tumor immunity [<a href="#ref-1">1</a>].

6.2 Pharmacogenomic Applications

HLA-DRB1 genotyping is clinically implemented for:

• Abacavir hypersensitivity: Although the primary association is with HLA-B*57:01, HLA-DRB1*07:01 is in linkage disequilibrium and may contribute to the CD4+ T-cell response.
• Allopurinol-induced SCARs: HLA-B*58:01 is the primary risk allele, but HLA-DRB1*15:01 provides additional risk stratification in Asian populations.
• Drug-induced liver injury (DILI): HLA-DRB1*15:01 is associated with flucloxacillin-induced DILI, and HLA-DRB1*07:01 with co-amoxiclav-induced DILI. Pre-emptive genotyping is recommended in high-risk populations.
• Immunogenicity of biologics: Anti-drug antibodies (ADAs) against therapeutic monoclonal antibodies (e.g., infliximab, adalimumab) are more likely to develop in patients carrying certain HLA-DRB1 alleles (e.g., *03:01), leading to reduced drug efficacy and infusion reactions [<a href="#ref-1">1</a>].

6.3 Gene Therapy and CRISPR Approaches

Emerging gene-editing strategies aim to:

• Knock out HLA-DRB1 in allogeneic CAR-T cells to prevent graft-versus-host disease (GvHD) and host-versus-graft rejection. CRISPR-Cas9-mediated disruption of the β2-microglobulin gene (for MHC class I) and CIITA (for MHC class II) generates "universal" donor cells that evade both CD8+ and CD4+ T-cell responses.
• Introduce protective alleles: In autoimmune diseases, gene therapy to replace susceptible HLA-DRB1 alleles with protective ones (e.g., *13:01) is theoretically possible but faces significant technical and ethical hurdles.
• Engineer HLA-DR-restricted TCRs: TCR gene therapy using HLA-DR-restricted TCRs specific for tumor antigens is being explored for solid tumors, though challenges include TCR mispairing and off-target toxicity [<a href="#ref-1">1</a>].

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance

References